| 15.23 0.63 (4.32%) | 03-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.24 | 1-year : | 22.64 |
| Resists | First : | 17.33 | Second : | 19.38 |
| Pivot price | 15.59  |
|||
| Supports | First : | 14 | Second : | 11.64 |
| MAs | MA(5) : | 15.55 |
MA(20) : | 15.97 |
| MA(100) : | 18.45 |
MA(250) : | 14.2 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 39.3 |
D(3) : | 41.5 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 25 | Low : | 6.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DYN ] has closed above bottom band by 32.8%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.57 - 15.65 | 15.65 - 15.72 |
| Low: | 14.24 - 14.32 | 14.32 - 14.39 |
| Close: | 15.1 - 15.23 | 15.23 - 15.35 |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Wed, 04 Mar 2026
DYN: FORCE platform drives clinical and commercial progress in rare muscle diseases, with multiple launches ahead - TradingView
Wed, 04 Mar 2026
DYN: Validated platform and pipeline set stage for multiple rare disease launches and growth - TradingView
Wed, 04 Mar 2026
Dyne Therapeutics, Inc. $DYN Shares Acquired by Vanguard Group Inc. - MarketBeat
Tue, 03 Mar 2026
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Potential 142% Upside in the Biotech Arena - DirectorsTalk Interviews
Tue, 03 Mar 2026
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Mon, 02 Mar 2026
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.6% After Earnings Miss - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 165 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 112.5 (%) |
| Shares Short | 19,190 (K) |
| Shares Short P.Month | 17,300 (K) |
| EPS | -3.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.4 % |
| Return on Equity (ttm) | -60.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -376 (M) |
| Levered Free Cash Flow | -242 (M) |
| PE Ratio | -4.21 |
| PEG Ratio | 0 |
| Price to Book value | 3.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|